# Jiankai Liang

## List of Publications by Year in descending order



| | | | |
|---|---|---|---|
| 22 papers | 614 citations | 687363 13 h-index | 677142 22 g-index |
| 23 all docs | 23 docs citations | 23 times ranked | 732 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Identification of the receptor of oncolytic virus M1 as a therapeutic predictor for multiple solid tumors. Signal Transduction and Targeted Therapy, 2022, 7, 100. | 17.1 | 17 |
| 2 | Overcoming resistance to oncolytic virus M1 by targeting PI3K-Î³ in tumor associated myeloid cells. Molecular Therapy, 2022, , . | 8.2 | 1 |
| 3 | Real-Time Visualization and Quantification of Oncolytic M1 Virus In Vitro and In Vivo. Human Gene Therapy, 2021, 32, 158-165. | 2.7 | 11 |
| 4 | Necroptotic virotherapy of oncolytic alphavirus M1 cooperated with Doxorubicin displays promising therapeutic efficacy in TNBC. Oncogene, 2021, 40, 4783-4795. | 5.9 | 26 |
| 5 | Visualization of the Oncolytic Alphavirus M1 Life Cycle in Cancer Cells. Virologica Sinica, 2021, 36, 655-666. | 3.0 | 4 |
| 6 | Tumors driven by RAS signaling harbor a natural vulnerability to oncolytic virus M1. Molecular Oncology, 2020, 14, 3153-3168. | 4.6 | 7 |
| 7 | Lonidamine potentiates the oncolytic efficiency of M1 virus independent of hexokinase 2 but via inhibition of antiviral immunity. Cancer Cell International, 2020, 20, 532. | 4.1 | 5 |
| 8 | Zinc-finger antiviral protein acts as a tumor suppressor in colorectal cancer. Oncogene, 2020, 39, 5995-6008. | 5.9 | 12 |
| 9 | Systematic Characterization of the Biodistribution of the Oncolytic Virus M1. Human Gene Therapy, 2020, 31, 1203-1213. | 2.7 | 17 |
| 10 | Intravenous injection of the oncolytic virus M1 awakens antitumor T cells and overcomes resistance to checkpoint blockade. Cell Death and Disease, 2020, 11, 1062. | 6.3 | 32 |
| 11 | Negative regulation of miRâ€1275 by H3K27me3 is critical for glial induction of glioblastoma cells. Molecular Oncology, 2019, 13, 1589-1604. | 4.6 | 13 |
| 12 | Inhibition of the mevalonate pathway enhances cancer cell oncolysis mediated by M1 virus. Nature Communications, 2018, 9, 1524. | 12.8 | 21 |
| 13 | Deficiency of the IRE1Î±-Autophagy Axis Enhances the Antitumor Effects of the Oncolytic Virus M1. Journal of Virology, 2018, 92, . | 3.4 | 11 |
| 14 | Selective Antagonism of Bcl-xL Potentiates M1 Oncolysis by Enhancing Mitochondrial Apoptosis. Human Gene Therapy, 2018, 29, 950-961. | 2.7 | 13 |
| 15 | DNA-PK inhibition synergizes with oncolytic virus M1 by inhibiting antiviral response and potentiating DNA damage. Nature Communications, 2018, 9, 4342. | 12.8 | 38 |
| 16 | The Anti-Warburg Effect Elicited by the cAMP-PGC1Î± Pathway Drives Differentiation of Glioblastoma Cells into Astrocytes. Cell Reports, 2017, 18, 468-481. | 6.4 | 85 |
| 17 | Selective replication of oncolytic virus M1 results in a bystander killing effect that is potentiated by Smac mimetics. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 201701002. | 7.1 | 33 |
| 18 | Targeting VCP enhances anticancer activity of oncolytic virus M1 in hepatocellular carcinoma. Science Translational Medicine, 2017, 9, . | 12.4 | 55 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Naturally Existing Oncolytic Virus M1 Is Nonpathogenic for the Nonhuman Primates After Multiple Rounds of Repeated Intravenous Injections. Human Gene Therapy, 2016, 27, 700-711. | 2.7 | 37 |
| 20 | Activation of Cyclic Adenosine Monophosphate Pathway Increases the Sensitivity of Cancer Cells to the Oncolytic Virus M1. Molecular Therapy, 2016, 24, 156-165. | 8.2 | 35 |
| 21 | A classical PKA inhibitor increases the oncolytic effect of M1 virus via activation of exchange protein directly activated by cAMP 1. Oncotarget, 2016, 7, 48443-48455. | 1.8 | 23 |
| 22 | Identification and characterization of alphavirus M1 as a selective oncolytic virus targeting ZAP-defective human cancers. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E4504-12. | 7.1 | 118 |